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Localization of Metastases from Medullary Thyroid Carcinoma Using 
Different Methods 
Rosa C. Cabezas,* Luis Berna,* Montserrat Estorch,* Ignacio Carrio,' and Angeles 
Garcia-Ameijeiras* 
We analyzed the efficiency of three different noninvasive methods in the localization of recurrent 
medullary thyroid carcinoma (MTC). Nine patients (six females and three males) with biochemical 
evidence of disease afler primary surgery were subjected to anti-carcinoembryonic antigen (anti-
CEA) antibody, meta-iodo-benzylguanidine (MIBG), and computed tomography. Another female 
patient, in biochemical remission for six years after initial surgery, was also studied using the same 
methods. Three of the ten patients had negative results with all three methods (including the patient in 
remission). The other seven patients showed abnormal uptake of labeled anti-CEA antibody in various 
localizations: only two of these patients had a corresponding pathological image hy computed 
tomography and only one by "'/ MIBG. These preliminary results suggest thatanti-CEA scanning 
may be the most sensitive noninvasive method for the localization of MTC recurrences. (Henry Ford 
Hosp MedJ 1989:37:169-72) 
Medullary thyroid carcinoma (MTC) patients, both heredi-tary and sporadic, often have clinical and biochemical evi-
dence of disease recunence after primary surgery (1-3). Since 
surgery is the effective therapy for the disease (4-6) (either pri-
mary or secondary), localization ofthe cancer tissue and its dis-
semination is of primary importance. 
Several localization methods have been used, from conven-
tional plain chest roentgenograms to computed tomography and 
" ' I meta-iodo-benzylguanidine (MIBG) scans, with variable 
degrees of efficiency (7-13). Some authors have also advocated 
the use of invasive techniques, such as venous catheterization, 
but this limits the areas studied and hence metastases in un-
suspected organs may be missed (14). 
Since all forms of MTC are known to express and secrete car-
cinoembryonic antigen (CEA) (15,16) and labeled monoclonal 
antibodies against it have been developed for human scintiscan-
ning, we studied the ability of such an antibody to detect the 
presence of recurrent MTC and compared the results with those 
obtained in the same patients using '^ '1 MIBG and computed to-
mography as the means of detection. Previous studies (17,18) 
have shown that '^^'I anti-CEA antibodies were u.seful for the de-
tection of MTC, although the number of patients studied was 
small. 
a sternotomy a few months before the tests were performed. 
Case 9's MTC was diagnosed by family screening; she had ' " I 
anti-CEA scanning prior to surgery. On physical examination 
the thyroid gland was considered normal. Bilateral microscopic 
foci of MTC, with positive immunostaining for CEA, were 
found in the thyroid. Two patients (cases 6 and 8) had extemal 
neck radiation after initial surgery. Calcitonin (CT) was elevated 
in all patients except case 10, and five patients had high tevels of 
CEA. Three patients had hereditary MTC, whereas the other six 
had an apparently sporadic form of MTC. None was diagnosed 
as having multiple endocrine neoplasia type 2, 
Materials and Methods 
CT measurements were performed by radioimmunoassay 
using a commercial kit (Calcitonin II RIA, tncstar Corporation, 
Stillwater, MN). CT stimulation tests were performed as de-
scribed previously (19). For the '^'t anti-CEA and the ' ^ ' I MIBG 
scans, the patients had thyroid remnant blockage with Lugot 
drops for a total of nine days, starting two days prior to the injec-
tion of the labeled compound. Potassium perchlorate (I g orally) 
was administered two hours prior to the injection and every 12 
Patients 
The patients' data are summarized in Table 1. We studied ten 
patients, seven females and three mates, with mean ages of 
42.14 ± 11.79 years and 46.33 ± 3.05 years, respectivety. The 
follow-up period averaged 7.19 ± 4.09 years. Atl patients ex-
cept case 9 had neck surgery for MTC; one ofthese patients had 
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Table I 
Descriptive Data of All Patients 
Case 
Age al 
Diagnosis Sex 
Basal CT 
(pg/raL) 
Poststiraulatory 
CTPeak 
( p g / i i i L ) 
CEA 
P-g/L 
1 49 M 280 915 <2.5 
: 5.^  F 300 868 5.85 
3 43 M >500 9,954 94.25 
4 47 M > 10.000 
— 6.6 
5 f 689 
— 
11.15 
6 4(. F 3 l.s 
— 
1 
7 47 F 4,SI 852 30.72 
8 32 F 311 
— 2.85 
9 22 F 63 500 2.5 
10 40 F Undetectable Undetectable <2.5 
Normal CT levels are « IOO pg/mL for males and s 45 to 50 pg/mL for females. Nonnal 
ptiststimulatory CT levels are s 500 pg/mL for males and ss 200 pg/mL for females. 
Normal CEA is < 5 jig/L. 
Table 2 
Results of MTC Localization Techniques 
Coraputed 
Case Anti-CEA Tomography MIBG Surgery 
1 -1- LM Normal Normal Not Done 
2 Norraal Normal Normal Not Done 
3 4- BM -1- BM Not Done ( + ) 
4 3- Neck 4- Neck Normal ( + ) 
BM BM 
5 J- Neck Normal Norraal Not Done 
6 -1- Neck Normal 3- Neck Not Done 
7 3- LM Normal Norraal Not Done 
8 Norraal -1- (subpleural + (R Not Done 
L Nodule) paracardiac 
uptake) 
9 4- Neck Not Done Not Done ( + ) 
10 Normal Normal Norraal 
— 
R = right. L = left, B = bilateral, and M = media.stinum. 
hours (250 mg) for seven days thereafter The '^ ' I anti-CEA 
scans were performed with 1 mg of the F(ab')2 fraction of anti-
CEA monoclonal antibody (Sorin, Biomedica, Italy) injected 
intravenously, Whote body planar scans were taken at two, five, 
and seven days postinjection in anterior and posterior projec-
tions, using a conventional targe field of view camera with a 
high energy collimator, 20% w centered on a 360 Kev peak. 
Analog and digital images of 500 K counts each collected on a 
128 X 128 matrix were stored for subsequent analysis. 
Within 15 days of the ' ^ ' I anti-CEA scan, and using a similar 
procedure, whole body planar scans at 24, 48, and 72 hours 
after intravenous administration of I mCi of " ' I MIBG were ob-
tained in eight patients. 
Cervical, thoracic, and abdominal computed tomography 
scans were perfonned in nine patients on a Siemens Somaton 
whole body scanner, operating at 125 Kvp and 230 mAs, with a 
5 second scan time and at 8 mm slice thickness. 
Results 
"'I anti-CEA 
Best results were obtained in the studies performed seven 
days after the intravenous injection. Case 10, who had been in 
biochemical remission for six years, had a normal scintiscan, 
whereas seven of nine patients with active disease had patholog-
ical uptake (Table 2). One such abnormal scan is shown in Fig 1. 
Three patients had abnormal uptake in the cervical area, one in 
the bilateral superior mediastinum and low cervical bed, one bi-
laterally in the mediastinum, and two in the left mediastinum 
(Fig 2). These results are summarized in Table 2. Case 3 had the 
tests performed on two occasions within ten months, and the re-
sults were identical on alt occasions. 
i^ 'I MIBG 
Only two of the eight patients studied had abnormal uptakes: 
one patient had a positive uptake in the cervical area, which was 
also observed in the " ' I anti-CEA study, and the other patient 
had an abnormal right paracardiac uptake which in subsequent 
reviews was thought to be an artifact. This patient atso had a left 
subpleural nodule detected by computed tomography which was 
not considered tumoral. 
None of the patients had any adverse reactions to the admin-
istered radiolabeled compounds. 
Computed tomography 
Two of nine patients who had computed tomography scans 
had pathological images compatible with metastases in the para-
tracheat and infraclavicular nodes. Both had abnormal ' " I anti-
CEA uptake in the same areas. 
Other data 
Three of seven patients with abnormal ' -" I anti-CEA uptake 
have had surgery. Immunohistochemical anatysis of the resected 
tissues confirmed the presence of MTC in each. Complete nor-
malization of the CT and CEA levels was observed after surgery 
in only one of these three patients; one patient is awaiting right 
thoracotomy and the other has had a decrease of the CT levels 
postoperatively. One patient has refused surgery or any other in-
vasive procedure, and another prefened extemal radiation when 
offered by a physician from another institufion. The other re-
maining patients are awaiting surgery. 
Discussion 
Early detection of recunent MTC is of primary importance 
since the patients' prognosis invariably worsens with the ad-
vance of the disease (15,19,20), which is partly due to the lack of 
effective therapy other than surgery (21,22). It is important to 
realize that between 50% and 70% of MTC patients already have 
metastases at the time of diagnosis and that approximately 50% 
will develop them thereafter (2-4). 
Detection of primary and recurrent disease is now possible 
through the determinations of basal and/or poststimulatory lev-
els of CT (1,2,19). High postoperative levels of CT are consid-
ered clear evidence of persistence of the disease, especially 
when an exaggerated response to the conventional secre-
tagogues (either pentagastrin alone or pentagastrin combined 
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Fig 1—Anterior view ofa "'I anti-CEA scan showing uptake in 
a local neck recurrence 11 years after surgery. 
Fig 2—anti-CEA scan (posterior view) showing uptake in 
mediastinal nodes. 
with calcium) is observed. In our experience, high basal or 
poststimulatory levets of CT after surgery (in seram obtained as 
earty as one week after initial thyroidectomy) were always fol-
lowed by increasing CT tevels in the subsequent determinations, 
which strongly suggests persistence of disease. 
Although diagnosis of disease persistence is cunently possi-
ble, localization of the metastases and, possibly more impor-
tant, determination of the extent of the disease have proved to be 
difficult in many cases. Previous reports have suggested that " ' I 
MIBG is a useful toot for detecfion of MTC (7-13). However, 
others have found poor sensitivity of the technique (18). In our 
study (Tabte 2), onty one of eight patients had an abnormal ' ^ ' I 
MIBG uptake (case 8's resutts proved to be false-negative). Two 
patients had the test performed on more than one occasion 
within a two-year period with identical results. 
Eight of nine patients with biochemical evidence of active 
MTC had computed tomography scans performed (some on 
multiple occasions), but tumor localization was possible in onty 
two of these patients. Since our computed tomography studies 
were performed at 8 mm cuts, smaller metastases may have been 
missed; two of our patients had muttiple nodes that were not de-
tected by this technique, presumably because of their small size, 
tdentification of normal neck stractures can be difficult in cer-
vical computed tomography scanning after certain types of pro-
cedures are done. 
In OIU- study " ' I anti-CEA F(ab')2 antibody fragment proved 
to be the most sensitive technique. Although only a small 
number of patients were studied and we lack histologic proof in 
all cases, our results suggest that this technique may be valuabte 
in the localization of MTC sites. In case 9, who has normal CEA 
values and the hereditary type of MTC diagnosed by famity 
screening, the ' ^ ' I anti-CEA uptake was posifive onty in the cer-
vical area. No macroscopic thyroid nodules were seen at thy-
roidectomy. Her CT levels remained undetectable 
postoperatively. Results in this patient indicate that even micro-
scopic MTC can be detected by " ' I anri-CEA scanning. It could 
be argued that the remaining normal thyroid had accumulated 
free " ' I . However, the administration of ' ^ ' I blocking agents 
prior to and during the seven days of the test would have pre-
vented the uptake by the nonnal thyroid. We have used the same 
procedure as that used in gastrointestinal cancer patients whose 
thyroid glands are intact and in whom free '^'t thyroid uptake is 
not seen. 
Case to, who was in biochemical and clinical remission for 
six years, had a negative ' ^ ' I anti-CEA uptake. Although this 
may indicate that the test is reliabte with respect to negative re-
sutts, the tack of uptake in cases 2 and 8 (both with moderately 
elevated CT levels) refutes this assumption. Whether the pa-
fients who showed uptake in some areas did not have other, as yet 
undetected, metastases remains to be seen. Of the three patients 
operated on, one stilt shows inexplicably high CT levels, al-
though the ' ^ ' I anti-CEA resutts are negative. No false-positive 
results for this test have been found. Since not atl patients have 
had surgery, no firm conctusion can yet be made. 
Although we have not observed any adverse reactions in the 
patients studied, this possibility cannot be excluded. Since the 
test may be repeated several times, it is possible that some pa-
tients may develop blocking anti-idiotypic antibodies against 
the F(ab'), anti-CEA fragment rendering it inactive. 
Our resutts suggest that, of the ttiree techniques studied, " ' I 
anti-CEA screening is the most sensitive and promising tech-
nique, although studies in larger patient populations are needed. 
Henry Ford Hosp Med J—Vol 37. Nos 3 & 4. 1989 Detection of MTC Metastases—Cabezas et al 171 
Acknowledgments 
We thank Mrs. Angeles Rodriguez for her secretarial 
assistance. 
This work was supported by FISS grants 87/927 and 
89/0023. 
References 
1. Graze K, Spiler IJ, Tashjian AH Jr, et al. Natural history of familial medul-
lary thyroid carcinoma: Effect of a program for early diagnosis. N Engl J Med 
1978;299:980-5. 
2. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thy-
roid: A study of the clinical features and prognostic factors in 161 patients. Medi-
cine 1984;63:319-42. 
3. Chong GC, Beahrs OH, Sizemore GW, Woolner LH. Medullary car-
cinoraa of the thyroid gland. Cancer 1975;35:695-704. 
4. Russell CF, Van Heerden JA, Sizemore GW, et al. The surgical manage-
raent of medullary thyroid carcinoma. Ann Surg 1983;197:42-8. 
5. Norton JA, Doppman JL, Brennan MF, Localization and resection of 
clinically inapparent medullary carcinoma of the thyroid. Surgery 
1980;87:616-22. 
6. Tisell LE. HaussonG, Jansson S, Salander H. Reoperation in the treatment 
of asymptomatic metastasizing raedullary thyroid carcinoma. Surgery 
1986:99:60-6. 
7. Endo K. Shiomi K, Kasagi K, el al. Imaging of raedullary thyroid cancer 
wilh i"I-MlBG. Lancel I984;2:233. 
8. Connell JMC, Hilditch TE, Elliot A, Scrapie PE I-131-MIBG and raedul-
lary carcinoraa ofthe thyroid (Leiter). Lancet 1984;2:1273-4. 
9. Sone T, Fukunaga M, Otsuka N, et al. Metastatic medullary thyroid can-
cer: Localization with iodine-131 raetaiodobenzylguanidine. J Nucl Med 
1985;26:604-8. 
10. Ansari AN, Siegel ME, De Qualtro V, Gazarian LH. Iraaging of raedul-
lary thyroid carcinoraa and hypert'unclioning adrenal medulla using iodine-131 
metaiodobenzylguanidine. J Nucl Med 1986;27:1858-60. 
11. Baulieu JL, Guilloleau D, Delisle MJ, et al. Radioiodinated meta-
iodobenzylguanidine uptake in raedullary thyroid cancer: A French cooperalive 
study Cancer 1987;60:2189-94. 
12. Pcrdrisot R, Rohmer V, Lejeune JJ, Bigorgne JC, Jallet P. Thyroid uptake 
of MIBG in Sipple's syndrome. Eur J Nucl Med 1988;14:37-8. 
13. Guilloleau D, Baulieu JL, Besuard JC. Medullary thyroid carcinoraa 
imaging in an animal model: Use of radiolabeled anticalcitonin F(ab'), and 
meta-iodobenzylguantdine. EurJ Nucl Med 1985:11:198-200. 
14. Mrad MDB, Gardel P, Roche A, et al. Value of venous catheterization and 
calcitonin studies in the treatraent and raanagement of clinically inapparent 
medullary thyroid carcinoma. Cancer 1989;63:133-8. 
15. Schroder S, Bocker W, Baisch H, et al. Prognostic factors in medullary 
thyroid carcinomas: Survival in relalion lo age. sex. stage, histology, immu-
nocytocheraistry, and DNA content. Cancer 1988:61:806-16. 
16. Rougier PV, Calraeltes C, Laplanche A, et al. The values of calcitonin 
and carcinoerabryonic antigen in the treatraent and managemeni of nonfamilial 
medullary thyroid carcinoma. Cancer 1983:51:855-62. 
17. Berche C, Mach JP, Lumbroso JD, el al. Toraoscihligraphy for detecting 
gastrointestinal and raedullary thyroid cancers: Firsl clinical results using radio-
labelled monoclonal antibodies against carcinoerabryonic antigen. Br Med J 
1982:285:1447-51. 
18. Hoefnagel CA. Delprat CC. Zauw D. van Der Schoot JB. New radio-
nuclide tracers for the diagnosis and therapy of medullary thyroid carcinoraa. 
Clin NucIMed 1988:13:159-65. 
19. Wells S Jr, Baylin SB, Leight GS, Dale JK, Dilley WG, Famdon JR. Thc 
importance of carly diagnosis in patients with hereditary medullary thyroid car-
cinoma. Ann Surg 1982;195:595-9. 
20. Hay ID. Prognostic factors in thyroid carcinoraa. Thyroid Today 
1989;12:1-9. 
21. Saraaan NA. Schultz PN. Hickey RC. Medullary thyroid carcinoraa: 
Prognosis of farailial versus sporadic disease and the role of radiotherapy. J Clin 
Endocrinol Melab 1988:67:801-5. 
22. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: A review. 
Semin Oncol 1987;14:34.3-53. 
172 Henry Ford Hosp Med J —Vol 37, Nos 3 & 4, 1989 Detection of MTC Metastases—Cabezas et al 
